lyophilization raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-02 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
定量分析的主流方法是反相高效液相色谱联用紫外或质谱检测，利用肽在疏水固定相上的保留行为确定纯度与含量。对于生物基质中的浓度测定，常采用液相色谱串联质谱，并配合固相萃取或蛋白沉淀进行样品前处理。免疫分析法也可使用，但可能受到结构相关肽的交叉反应干扰。
纯度评估通常综合反相色谱、体积排阻色谱与质谱三方面信息：前者反映疏水性杂质，后者反映聚集体，质谱则确认分子量与主要降解产物。有关降解途径的完整图谱——例如脱酰胺、氧化与水解各占多大比例——在不同储存条件下仍有差异，属于需要逐案验证的问题。
(phosphatase 2A protein)-leucine-carboxy methyltransferase (EC 2.1.1.233) is an enzyme with systematic name S-adenosyl-L-methionine:(phosphatase 2A protein)-leucine O-methyltransferase. This enzyme catalyses the following chemical reaction
=== Epidemiology === Kalra has been the lead or senior author of several epidemiological studies in the field of obesity. In addition to using national datasets, he has served as a regional lead investigator for Haryana in the ICMR-funded INDIAB Study. Multiple papers from this cohort have been published, including national obesity prevalence data in The Lancet and several other studies. He has also contributed to studies assessing the prevalence of obesity-related comorbidities, including steatotic liver disease. Kalra is the senior author of a major analysis from the Comprehensive National Nutrition Survey, reporting the prevalence of childhood obesity in India. From the Longitudinal Ageing Study in India, he has also led work reporting the first national estimates of sarcopenia and sarcopenic obesity in older adults.
== History == In 1822 the first awards were given to thirteen people by the Philadelphia Society for Promoting Agriculture entrusted by the "Corporation of the city of Philadelphia". The druggist John Scott of Edinburgh organized a $4,000 fund which, after his death in 1815 was administered by a merchant until the first award, a copper medal and "an amount not to exceed twenty dollars", was given in 1822. (At the time, $20 could buy one ox or a 12-volume encyclopedia.) Several hundred recipients have since been selected by the City Council of Philadelphia, which decides from the annual list of nominees made by the Franklin Institute.
Sources: en.wikipedia.org
Eloralintide (LY3841136) is an experimental drug that works as a selective amylin receptor agonist. It was designed to activate the amylin receptor without off-target effects at the calcitonin receptor. In a recent US randomised controlled trial of obese patients (mean bodyweight 109 kg, mean BMI 39 kg/m2), those receiving the highest assessed dose showed a 20 percent reduction in body weight over the 48 week study period when compared to placebo.
== Mechanism == A number of possible mechanisms for overtraining have been proposed. One stipulates that microtrauma to the muscles are created faster than the body can heal them. Another proposes that amino acids are used up faster than they are supplied in the diet, a condition sometimes referred to as "protein deficiency". Finally, systemic inflammation has been considered as a mechanism in which the release of cytokines activates an excessive immune response.
==== 2100–2199 ==== Animals (Scientific Procedures) Act (Amendment) Regulations 1993 (S.I. 1993/2102) Animals (Scientific Procedures) Act(Amendment) Order 1993 (S.I. 1993/2103) Closure of Prisons (H.M. Young Offender Institution Campsfield House) Order 1993 (S.I. 1993/2104) Gas (Authorisation Application) (Amendment) Regulations 1993 (S.I. 1993/2105) Nurses, Midwives and Health Visitors (Midwives Amendment) Rules Approval Order 1993 (S.I. 1993/2106) London South Circular Trunk Road (A205)(Thurlow Park Road, Lambeth) (Prohibition of Right Turn) Order 1993 (S.I. 1993/2107) Social Security (Claims and Payments) Amendment (No. 3) Regulations 1993 (S.I. 1993/2113) Airports (Designation) (Removal and Disposal of Vehicles) (Amendment) Order 1993 (S.I. 1993/2117) Housing Benefit and Council Tax Benefit (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/2118) Income-related Benefits Schemes (Miscellaneous Amendments) (No. 4) Regulations 1993 (S.I. 1993/2119) Goods Vehicles (Operators' Licences) (Temporary Use in Great Britain) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/2120) Air Navigation (Restriction of Flying) (High Security Prisons) (Amendment No. 3) Regulations 1993 (S.I. 1993/2123) Winchester–Preston Trunk Road (A34) (Newbury Bypass Detrunking) (No.2) Order 1993 (S.I. 1993/2128) Winchester–Preston Trunk Road (A34) (Newbury Bypass) Slip Roads (No.3) Order 1993 (S.I. 1993/2129) East Worcester and Severn Trent Water (Amendment of Local Enactments etc.) Order 1993 (S.I. 1993/2130) County Court Appeals (Amendment) Order 1993 (S.I.
==== Primary hyperparathyroidism and parathyroid adenoma ==== In the context of primary hyperparathyroidism (PHPT), 68Ga-Trivehexin PET/CT was successfully applied for PET imaging of disseminated parathyroid adenoma (PTA). In a 13-patient cohort, a PTA detection rate of 94.1% was found. A retrospective analysis of 38 PHPT patients determined a lesion-based detection rate of 98% (49/50), and yet another study in 44 patients found a sensitivity of 97.3% and a PPV of 100% compared to a composite reference standard of Technetium (99mTc) sestamibi scintigraphy and ultrasound (US). 68Ga-Trivehexin PET/CT was furthermore used for delineation of osteolysis-associated brown tumors which occur as a result of persistent hyperparathyroidism.
Sources: en.wikipedia.org
== Anterior vaginal support == Not all agree to the amount of supportive tissue or fascia exists in the anterior vaginal wall. The major point of contention is whether the vaginal fascial layer exists. Some texts do not describe a fascial layer. Other sources state that the fascia is present under the urethra which is embedded in the anterior vaginal wall. Despite disagreement, the urethra is embedded in the anterior vaginal wall.
In 1927, Max Oberlin studied the pharmacology of MDMA while searching for substances with effects similar to adrenaline or ephedrine, the latter being structurally similar to MDMA. Compared to ephedrine, Oberlin observed that it had similar effects on vascular smooth muscle tissue, stronger effects at the uterus, and no "local effect at the eye". MDMA was also found to have effects on blood sugar levels comparable to high doses of ephedrine. Oberlin concluded that the effects of MDMA were not limited to the sympathetic nervous system. Research was stopped "particularly due to a strong price increase of safrylmethylamine", which was still used as an intermediate in methylhydrastinine synthesis. Albert van Schoor performed simple toxicological tests with the drug in 1952, most likely while researching new stimulants or circulatory medications. After pharmacological studies, research on MDMA was not continued. In 1959, Wolfgang Fruhstorfer synthesized MDMA for pharmacological testing while researching stimulants. It is unclear if Fruhstorfer investigated the effects of MDMA in humans. Outside of Merck, other researchers began to investigate MDMA. In 1953 and 1954, the United States Army commissioned a study of toxicity and behavioral effects in animals injected with mescaline and several analogues, including MDMA. Conducted at the University of Michigan in Ann Arbor, these investigations were declassified in October 1969 and published in 1973.
Paul Leonard-Morgan wrote the film's industrial music score. Leonard-Morgan created music to suit the film's futuristic setting. He experimented with band-based music, but decided it sounded over-produced and too safe. He turned to electronic music and used 1980s-style synthesisers and modern sound modules to create various combinations and applied distortion and other effects to the result. Leonard-Morgan said, "I was looking to create a timeless score which couldn't be placed in any particular era. So it's ended up being a cross between a modern dance track and evocative soundscapes." For scenes conveying the effect of the Slo-Mo narcotic, he composed new music with real instruments and then slowed the songs down to match the visuals, such that one second of his composed score could last ten minutes (slowed to 0.17% of original). He then added additional real-time score to the slowed track. An unofficially altered Justin Bieber song served as inspiration for the Slo-Mo theme. Garland said that Portishead instrumentalist Geoff Barrow "sent me a link to a Justin Bieber song slowed down 800 times and it became this stunning trippy choral music." Morgan recreated the effect based on the modified track, which was used in the finished film. The film used Bieber's music as a temporary placeholder during editing before the score was finalised. The film also features songs by artists including: "Poison Lips" by Vitalic; "Dubstride" by Yann McCullough and Gemma Kicks; "Snuffbox" by Matt Berry; "Pontiac Moon" by Robert J.
==== Optical tweezers ==== Optical tweezers have also been used to separate cells in droplets. Two droplets are mixed on an electrode array, one containing the cells, and the other with nutrients or drugs. The droplets are mixed and then optical tweezers are used to move the cells to one side of the larger droplet before it is split. For a more detailed explanation on the underlying principles, see Optical tweezers.
===== Reactions ===== WHO director-general Tedros Adhanom, who was not directly involved with the investigation, said he was ready to dispatch additional missions involving specialist experts and that further research was required. He said in a statement, "Some explanations may be more probable than others, but for now all possibilities remain on the table." He also said, "We have not yet found the source of the virus, and we must continue to follow the science and leave no stone unturned as we do." Tedros called on China to provide "more timely and comprehensive data sharing" as part of future investigations. News outlets noted that, though it was unrealistic to expect quick and huge results from the report, it "offered few clear-cut conclusions regarding the start of the pandemic", "failed to audit the Chinese official position at some parts of the report", and was "biased according to critics". Other scientists praised how the report details the pathways that can shed light on the origin, if explored later. After the publication of the report, politicians, talk show hosts, journalists, and some scientists advanced unsupported claims that SARS-CoV-2 may have come from the WIV. In the United States, calls to investigate a laboratory leak reached "fever pitch", fueling aggressive rhetoric resulting in antipathy towards people of Asian ancestry, and the bullying of scientists. The European Union, United States, and 13 other countries criticised the WHO-convened study, calling for transparency from China and access to the raw data and original samples.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
Water promotes hydrolysis and deamidation, so removing it slows degradation during transport and storage. The dry solid is also less prone to microbial growth than a solution. Reconstitution is therefore performed close to the point of use.